“The high CD4/CD8 ratio and suppressed products NK cell activity for were improved by methyl-B12 treatment.” The Japanese researchers state: “We conclude that vitamin B12 acts as an immunomodulator for hay cellular immunity.”11 fever B12 was used successfully in the treatment products of IgE-mediated skin disorders. The German researchers conclude that B12 (cobalamin) when applied to the skin one or more times per day exhibited “...excellent results in topical treatment of skin disorders and in particular of inflammatory and hyperproliferative skin ailments for and hay and/or cutaneous manifestations of illness which are immunologic in origin, e.g. psoriasis, atopic dermatitis, fever contact dermatitis, and other eczematous dermatitises...”12 Click here for Allergy medication online.

In products January 1997, 62 subjects who had been the placebos in the 1995 study were invited for to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent hay a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the fever B12 treatment, and 5 not. 12 products of the 15 reported for and hay at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received fever treatment, 1:4 products not having received treatment.8 A bioequivalence study showed that a 3000 mcg for and hay lozenge delivered an equivalent amount of cyanocobalamin fever and products to the blood for as a 15 mcg injection.9 From the spring hay to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or fever and products placebo) containing lozenge twice daily for 21 consecutive days. All subjects for also received C and B oral multivitamins for hay and fever 21 days. Twice daily subjects maintained a nine-week diary on sneezing, runny products nose, for nasal hay and fever congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) products use. In the post-treatment for period, the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) hay in fever total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10